Europe Diabetes Care Devices Market Industry: Market Size & Forecast 2026

The Europe diabetes care devices market covers the full spectrum of products used for diabetes management, ranging from blood glucose monitoring equipment to insulin delivery systems. Valued at approximately $10.11 billion in 2025, the market sits within a broader European context where diabetes affects roughly one in ten adults, creating sustained demand across both Type 1 and Type 2 diabetes care pathways. The segment includes conventional finger-prick meters, continuous glucose monitors, smart insulin pens, insulin pumps, and associated disposables such as test strips and infusion sets.

• •The market spans blood glucose monitoring devices, insulin delivery systems, and connected digital health platforms
• •An estimated 32 million people in the EU are living with diabetes, forming the core patient base for device manufacturers
• •Rising healthcare expenditure on chronic diseases and growing patient awareness of self-management tools support sustained demand

The primary engine of market growth is the rising incidence of diabetes across Europe, fueled by aging demographics, increasingly sedentary lifestyles, and rising obesity rates in both Western and Eastern European countries. Technological advancements in continuous glucose monitoring, including app-connected devices and minimally invasive sensor technologies, are broadening adoption beyond hospital settings into home and ambulatory care environments. Favorable policy developments, including national reimbursement reforms for CGM devices and EU regulatory fast-track pathways for innovative medical devices under the Medical Device Regulation framework, are lowering barriers to market entry and patient access.

• •Europe's aging population and rising obesity levels are increasing the prevalence of both Type 1 and Type 2 diabetes
• •Reimbursement reforms in countries including Germany, the UK, and France have expanded patient access to CGM and insulin pump technologies
• •The shift toward home-based care and remote patient monitoring, accelerated in part by post-pandemic healthcare delivery changes, is boosting demand for connected devices

The market is broadly segmented by product type, with the blood glucose monitoring segment, including both traditional meters and continuous glucose monitors, representing the largest share, followed by insulin delivery systems and insulin pumps. CGM technology is the fastest-growing sub-segment, driven by clinical evidence supporting improved glycemic outcomes and expanding reimbursement coverage. Geographically, Western Europe, led by Germany, the United Kingdom, France, and Italy, dominates the market in terms of revenue and device penetration, while Eastern Europe is emerging as a higher-growth region as healthcare infrastructure modernizes and CGM adoption accelerates.

• •CGM systems are outpacing traditional glucose meters in growth rate as clinical adoption widens and sensor technology improves
• •Western Europe accounts for the largest regional revenue share, with Germany and the UK being the leading national markets
• •Eastern Europe is projected to grow at a faster pace due to rising disease awareness, expanding insurance coverage, and improving healthcare access

What are the recent trends and outlook?

Looking forward, the market is trending toward integrated, closed-loop insulin delivery systems, often referred to as artificial pancreas technology, that automate glucose monitoring and insulin dosing with minimal patient intervention. Digital connectivity is becoming a standard expectation, with devices increasingly featuring smartphone apps, cloud-based data platforms, and interoperability with electronic health records. Patient auto-administration and remote monitoring capabilities are reducing reliance on clinical settings, while ongoing research into next-generation sensors and long-acting insulin formulations continues to expand the addressable market. While regulatory complexity under the EU MDR and variation in national reimbursement policies present challenges, the overall outlook remains positive, with structural demand fundamentals supporting long-term market expansion.

• •Closed-loop and hybrid closed-loop insulin delivery systems are gaining clinical traction, representing the next frontier in automated diabetes management
• •Smartphone-connected devices and digital health platforms are becoming standard, enabling real-time data sharing between patients and healthcare providers
• •Demand for app-connected devices and patient self-management tools is accelerating as digital health literacy improves across European populations